Kura Oncology (NASDAQ:KURA) Upgraded to Buy at ValuEngine

ValuEngine upgraded shares of Kura Oncology (NASDAQ:KURA) from a hold rating to a buy rating in a research report sent to investors on Tuesday, ValuEngine reports.

A number of other research analysts also recently weighed in on KURA. Zacks Investment Research downgraded shares of Kura Oncology from a buy rating to a hold rating in a research report on Tuesday, November 12th. Wedbush reiterated a positive rating on shares of Kura Oncology in a research note on Wednesday, September 4th. BidaskClub raised shares of Kura Oncology from a sell rating to a hold rating in a research report on Wednesday, November 27th. JMP Securities restated a market outperform rating and set a $22.00 price objective on shares of Kura Oncology in a research note on Thursday, September 5th. Finally, Cowen restated a buy rating on shares of Kura Oncology in a report on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Kura Oncology currently has a consensus rating of Buy and an average price target of $25.43.

NASDAQ KURA opened at $15.35 on Tuesday. Kura Oncology has a 52 week low of $12.30 and a 52 week high of $21.42. The company has a debt-to-equity ratio of 0.03, a quick ratio of 19.29 and a current ratio of 19.29. The stock’s 50 day moving average price is $15.09 and its two-hundred day moving average price is $16.83. The stock has a market capitalization of $722.32 million, a price-to-earnings ratio of -8.92 and a beta of 2.56.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.03. On average, equities research analysts forecast that Kura Oncology will post -1.53 EPS for the current year.

Several institutional investors have recently made changes to their positions in the company. Metropolitan Life Insurance Co NY grew its stake in shares of Kura Oncology by 9.8% in the third quarter. Metropolitan Life Insurance Co NY now owns 10,584 shares of the company’s stock valued at $161,000 after buying an additional 946 shares in the last quarter. Squarepoint Ops LLC raised its position in Kura Oncology by 232.8% during the third quarter. Squarepoint Ops LLC now owns 82,359 shares of the company’s stock worth $1,249,000 after acquiring an additional 57,615 shares in the last quarter. Great Point Partners LLC lifted its stake in Kura Oncology by 1.3% in the third quarter. Great Point Partners LLC now owns 3,086,053 shares of the company’s stock valued at $46,815,000 after acquiring an additional 38,253 shares during the last quarter. California State Teachers Retirement System lifted its stake in Kura Oncology by 19.8% in the third quarter. California State Teachers Retirement System now owns 53,475 shares of the company’s stock valued at $811,000 after acquiring an additional 8,854 shares during the last quarter. Finally, State Street Corp lifted its stake in Kura Oncology by 52.0% in the third quarter. State Street Corp now owns 1,226,528 shares of the company’s stock valued at $18,606,000 after acquiring an additional 419,582 shares during the last quarter. Institutional investors own 88.72% of the company’s stock.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Featured Article: Intrinsic Value and Stock Selection

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit